Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

Louis Cantor, J. Hoop, L. Morgan, Darrell WuDunn, Yara Catoira-Boyle, Thomas Bournias, Louis Cantor, Monte Dirks, Efraim Duzman, Arash Mansouri, Thomas Mundorf, Steven Simmons, Robert Williams

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension. Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months. Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p≥0.741). After 6 months, both drugs significantly reduced IOP at every time point (p≤0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

Original languageEnglish
Pages (from-to)1370-1373
Number of pages4
JournalBritish Journal of Ophthalmology
Volume90
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Ocular Hypertension
Intraocular Pressure
Glaucoma
Pharmaceutical Preparations
Travoprost
Bimatoprost
Research Personnel
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. / Cantor, Louis; Hoop, J.; Morgan, L.; WuDunn, Darrell; Catoira-Boyle, Yara; Bournias, Thomas; Cantor, Louis; Dirks, Monte; Duzman, Efraim; Mansouri, Arash; Mundorf, Thomas; Simmons, Steven; Williams, Robert.

In: British Journal of Ophthalmology, Vol. 90, No. 11, 11.2006, p. 1370-1373.

Research output: Contribution to journalArticle

Cantor, L, Hoop, J, Morgan, L, WuDunn, D, Catoira-Boyle, Y, Bournias, T, Cantor, L, Dirks, M, Duzman, E, Mansouri, A, Mundorf, T, Simmons, S & Williams, R 2006, 'Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension', British Journal of Ophthalmology, vol. 90, no. 11, pp. 1370-1373. https://doi.org/10.1136/bjo.2006.094326
Cantor, Louis ; Hoop, J. ; Morgan, L. ; WuDunn, Darrell ; Catoira-Boyle, Yara ; Bournias, Thomas ; Cantor, Louis ; Dirks, Monte ; Duzman, Efraim ; Mansouri, Arash ; Mundorf, Thomas ; Simmons, Steven ; Williams, Robert. / Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. In: British Journal of Ophthalmology. 2006 ; Vol. 90, No. 11. pp. 1370-1373.
@article{9b19edd91e0442ab8e00ddd6c44674dc,
title = "Intraocular pressure-lowering efficacy of bimatoprost 0.03{\%} and travoprost 0.004{\%} in patients with glaucoma or ocular hypertension",
abstract = "Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension. Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months. Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p≥0.741). After 6 months, both drugs significantly reduced IOP at every time point (p≤0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9{\%}) with bimatoprost (n = 76) and 5.7 mm Hg (23.3{\%}) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3{\%}) and 5.2 mm Hg (22.4{\%}) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5{\%}) with bimatoprost and 4.5 mm Hg (18.9{\%}; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.",
author = "Louis Cantor and J. Hoop and L. Morgan and Darrell WuDunn and Yara Catoira-Boyle and Thomas Bournias and Louis Cantor and Monte Dirks and Efraim Duzman and Arash Mansouri and Thomas Mundorf and Steven Simmons and Robert Williams",
year = "2006",
month = "11",
doi = "10.1136/bjo.2006.094326",
language = "English",
volume = "90",
pages = "1370--1373",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

AU - Cantor, Louis

AU - Hoop, J.

AU - Morgan, L.

AU - WuDunn, Darrell

AU - Catoira-Boyle, Yara

AU - Bournias, Thomas

AU - Cantor, Louis

AU - Dirks, Monte

AU - Duzman, Efraim

AU - Mansouri, Arash

AU - Mundorf, Thomas

AU - Simmons, Steven

AU - Williams, Robert

PY - 2006/11

Y1 - 2006/11

N2 - Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension. Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months. Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p≥0.741). After 6 months, both drugs significantly reduced IOP at every time point (p≤0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

AB - Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension. Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months. Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p≥0.741). After 6 months, both drugs significantly reduced IOP at every time point (p≤0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

UR - http://www.scopus.com/inward/record.url?scp=33750716516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750716516&partnerID=8YFLogxK

U2 - 10.1136/bjo.2006.094326

DO - 10.1136/bjo.2006.094326

M3 - Article

VL - 90

SP - 1370

EP - 1373

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 11

ER -